Radiation Oncology Journal

  • 제29권3호
  • /
  • Pages.191-198
  • /
  • 2011
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix

  • Jeong, Bae-Kwon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Doo-Ho (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung-Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bae, Duk-Soo (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Byoung-Gie (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2011.09.19
  • Accepted : 2011.09.29
  • Published : 2011.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

Abstract

Purpose: Although the role of squamous cell carcinoma antigen (SCC-Ag) as a predictive and prognostic factor for uterine cervical cancer has been identified in previous studies, 1) the effective patient group of screening for recurrence with SCC-Ag, 2) the relationship between SCC-Ag and recurrence site, and 3) the relationship between the change of SCC-Ag and treatment outcome or recurrence have not been described. Materials and Methods: The study included 506 patients with histologically proven uterine cervical cancer between January 1994 and December 2010. We determining the serum SCC-Ag level before treatment and after treatment, and conducted a retrospective review of the patients' records. We evaluated the sensitivity and specificity of SCC-Ag for the detection of tumor recurrence by comparing biochemical recurrence with clinical recurrence. Results: The pretreatment SCC-Ag level and the proportion of patients over 1.5 ng/mL were higher in poor prognostic patient group. In the univariate and multivariate analysis, pretreatment SCC-Ag showed a statistically significant correlation with tumor size, International Federation of Gynecology and Obstetrics (FIGO) stage, pathology. In patients with biochemical recurrence vs. those without, 5-year DFS and OS were 27.6 vs. 92.7% (p ${\leq}$ 0.001) and 53.7 vs. 92.5% (p ${\leq}$ 0.001), respectively. Conclusion: Our study reconfirmed the known function of pretreatment SCC-Ag, but could not confirm the function of biochemical response as a predictive factor for treatment and as a prognostic factor. There was no statistically significant relationship between SCC-Ag level and recurrence site. We confirmed the role of SCC-Ag as a follow-up tool for recurrence of disease and which patient groups SCC-Ag was more useful for.

Keywords

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. https://doi.org/10.3322/caac.20107
  2. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat 2001;6:7-43.
  3. Classe JM, Rauch P, Rodier JF, et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol 2006;102: 523-9. https://doi.org/10.1016/j.ygyno.2006.01.022
  4. Ferrandina G, Legge F, Fagotti A, et al. Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures. Gynecol Oncol 2007;107:S127-32. https://doi.org/10.1016/j.ygyno.2007.07.006
  5. Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000;78:187-93. https://doi.org/10.1006/gyno.2000.5860
  6. Lai CH. Management of recurrent cervical cancer. Chang Gung Med J 2004;27:711-7.
  7. Chou HH, Wang CC, Lai CH, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001;51:442-8. https://doi.org/10.1016/S0360-3016(01)01628-5
  8. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res 2000;20:5113-5.
  9. Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in followup of patients with early-stage cervical cancer. J Clin Oncol 2001;19:3960-6.
  10. Forni F, Ferrandina G, Deodato F, et al. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys 2007;69:1145-9. https://doi.org/10.1016/j.ijrobp.2007.04.055
  11. Gadducci A, Tana R, Fanucchi A, Genazzani AR. Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol 2007;107:S23-6. https://doi.org/10.1016/j.ygyno.2007.07.033
  12. Hirakawa M, Nagai Y, Inamine M, et al. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol 2008;108:126-9. https://doi.org/10.1016/j.ygyno.2007.08.091
  13. Scambia G, Benedetti Panici P, Foti E, et al. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 1994;12:2309-16.
  14. Reesink-Peters N, van der Velden J, Ten Hoor KA, et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol 2005;23:1455-62. https://doi.org/10.1200/JCO.2005.02.123
  15. Molina R, Filella X, Lejarcegui JA, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol 2003;24:156-64. https://doi.org/10.1159/000073846
  16. Ohno T, Nakayama Y, Nakamoto S, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer 2003;97:3114-20. https://doi.org/10.1002/cncr.11453
  17. Ferrandina G, Macchia G, Legge F, et al. Squamous cell carcinoma antigen in patients with locally advanced cervical carcinoma undergoing preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Oncology 2008;74:42-9. https://doi.org/10.1159/000138979
  18. Ogino I, Nakayama H, Okamoto N, Kitamura T, Inoue T. The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy. Int J Gynecol Cancer 2006;16:1094-100. https://doi.org/10.1111/j.1525-1438.2006.00449.x
  19. Maiman M. The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol 2002;84:4-6. https://doi.org/10.1006/gyno.2001.6532
  20. Gaarenstroom KN, Kenter GG, Bonfrer JM, et al. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 2000;77:164-70. https://doi.org/10.1006/gyno.2000.5732
  21. Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol 2002;100:781-7. https://doi.org/10.1016/S0029-7844(02)02204-4

Cited by

  1. Prognostic Value of Different Patterns of Squamous Cell Carcinoma Antigen Level for the Recurrent Cervical Cancer vol.45, pp.1, 2013, https://doi.org/10.4143/crt.2013.45.1.48
  2. RAMAN SPECTROSCOPIC STUDY ON PREDICTION OF TREATMENT RESPONSE IN CERVICAL CANCERS vol.6, pp.2, 2011, https://doi.org/10.1142/s1793545813500144
  3. Is extended-field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer? vol.6, pp.None, 2014, https://doi.org/10.2147/cmar.s68262
  4. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis vol.35, pp.2, 2011, https://doi.org/10.1097/mnm.0000000000000026
  5. Expression and Effects of High-Mobility Group Box 1 in Cervical Cancer vol.15, pp.5, 2014, https://doi.org/10.3390/ijms15058699
  6. Application of Tumor Markers SCC-Ag, CEA, and TPA in Patients with Cervical Precancerous Lesions vol.15, pp.9, 2011, https://doi.org/10.7314/apjcp.2014.15.9.3911
  7. C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer vol.37, pp.1, 2011, https://doi.org/10.1007/s13277-015-3806-3
  8. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence vol.142, pp.1, 2011, https://doi.org/10.1016/j.ygyno.2016.04.029
  9. Relationship of 18F-FDG PET/CT metabolic, clinical and pathological characteristics of primary squamous cell carcinoma of the cervix vol.64, pp.8, 2011, https://doi.org/10.1136/jim-2016-000166
  10. Overexpression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related protein in cervical cancer and correlation with squamous cell carcinoma antigen vol.14, pp.3, 2011, https://doi.org/10.3892/ol.2017.6508
  11. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional vol.30, pp.1, 2011, https://doi.org/10.3802/jgo.2019.30.e1
  12. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer vol.14, pp.1, 2011, https://doi.org/10.1186/s13014-019-1355-4
  13. Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions vol.20, pp.1, 2020, https://doi.org/10.3892/ol.2020.11634
  14. Who can benefit from a lymph node boost in definitive chemoradiotherapy for node-positive cervical cancer: an evaluation of nodal failure in patients without nodal boost vol.61, pp.3, 2011, https://doi.org/10.1093/jrr/rraa012
  15. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional vol.25, pp.7, 2011, https://doi.org/10.1007/s10147-020-01664-3